Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been given an average rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $3.9375.

A number of equities analysts have weighed in on LUCD shares. Needham & Company LLC reissued a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research report on Thursday, November 13th. Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Institutional Trading of Lucid Diagnostics

Hedge funds have recently added to or reduced their stakes in the stock. Two Seas Capital LP acquired a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at $3,030,000. Ghisallo Capital Management LLC acquired a new stake in Lucid Diagnostics during the 3rd quarter valued at approximately $2,990,000. Aberdeen Group plc acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $2,525,000. Geode Capital Management LLC grew its holdings in Lucid Diagnostics by 420.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after acquiring an additional 1,274,194 shares during the period. Finally, Masters Capital Management LLC increased its holdings in Lucid Diagnostics by 46.6% in the third quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after purchasing an additional 1,272,000 shares in the last quarter. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Stock Performance

Shares of NASDAQ LUCD opened at $1.47 on Friday. The stock has a market capitalization of $202.39 million, a PE ratio of -1.41 and a beta of 1.22. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80. The stock has a 50 day moving average price of $1.21 and a 200 day moving average price of $1.15.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.